Prednisolone, Pentoxifylline Little Use in Alcoholic Hepatitis

This article originally appeared here.
Share this content:
Prednisolone, Pentoxifylline Little Use in Alcoholic Hepatitis
Prednisolone, Pentoxifylline Little Use in Alcoholic Hepatitis

THURSDAY, April 23, 2015 (HealthDay News) -- Prednisolone and pentoxifylline are associated with limited and no benefits, respectively, for severe alcoholic hepatitis, according to a study published in the April 23 issue of the The New England Journal of Medicine.

Mark R. Thursz, M.D., from Imperial College London, and colleagues examined the effect of treatment with prednisolone or pentoxifylline for severe alcoholic hepatitis. Patients were randomized to pentoxifylline-matched placebo and a prednisolone-matched placebo, prednisolone and a pentoxifylline-matched placebo, pentoxifylline and a prednisolone-matched placebo, or prednisolone and pentoxifylline. Data were available for 1,053 patients who underwent randomization.

The researchers found that 28-day mortality was 17 percent in the placebo-placebo group, 14 percent in the prednisolone-placebo group, 19 percent in the pentoxifylline-placebo group, and 13 percent in the prednisolone-pentoxifylline group. For 28-day mortality, the odds ratio was 1.07 (95 percent confidence interval, 0.77 to 1.49; P = 0.69) for pentoxifylline and 0.72 (95 percent confidence interval, 0.52 to 1.01; P = 0.06) for prednisolone. No significant between-group differences were seen at 90 days and one year.

"Pentoxifylline did not improve survival in patients with alcoholic hepatitis," the authors write. "Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or one year."

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »